EPR Properties vs Johnson & Johnson — how do they compare? EPR Properties trades at $61.2 (market cap $4.58B), while Johnson & Johnson trades at $260.51 (market cap $626.09B). The key difference: Johnson & Johnson is far larger — about 136.7× EPR Properties's market cap, and EPR Properties pays the higher dividend (6.22%). Which is the better fit depends on your goals.
| EPR | JNJ | |
|---|---|---|
Market Cap | $4.58B | $626.09B |
Sector | Real Estate | Health |
52-Week High | $64.32 | $267.24 |
52-Week Low | $48.71 | $172.78 |
Enterprise Value | $8.09B | $654.37B |
Dividend Yield | 6.22% | 2.06% |
Volume | — | 6,156,228 |
Signals from Pluang's Aura AI — not financial advice
EPR Properties (EPR) trades at $61.41, up 1.67% in the last session, with a bearish technical signal despite strong Q2 2026 FFO beating estimates. The company reported revenue growth to $699 million in 2026, though net income dipped to $263 million, and maintains a high gross margin of 91.41%. Recent news highlights dividend declarations and a new $1.6 billion credit facility, supporting its experiential real estate focus.
Outlook is mixed: analyst consensus favors 'Hold' with a $65.30 price target, indicating modest upside, but technical indicators and a slight earnings miss in Q1 2026 pose risks. Opportunities include dividend growth and portfolio diversification, while risks involve investing cash flow volatility and sector competition.
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
Trailing returns across standard periods
Latest headlines on both assets
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →